Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Yale University School of Medicine, New Haven, CT, USA.
Adv Ther. 2024 Nov;41(11):3982-3995. doi: 10.1007/s12325-024-02972-0. Epub 2024 Sep 14.
This paper explores the intricate relationship between depression, gut dysbiosis, and Clostridioides difficile infections, collectively termed "The 3 Ds". Depression is a widespread mental disorder increasing in prevalence. It is recognized for its societal burden and complex pathophysiology, encompassing genetic, environmental, and microbiome-related factors. The consequent increased use of antidepressants has led to growing concerns about their effects on the gut microbiome. Various classes of antidepressants and antipsychotics show antimicrobial activity, potentially leading to shifts in the gut microbiome and contributing to the development of dysbiosis. Dysbiosis, in turn, can predispose individuals to opportunistic infections like C. difficile, a significant healthcare concern due to its high recurrence rates and severe impact on patients' quality of life. Further, the link between antidepressant use and an increased risk of C. difficile infection (CDI) is explored and, finally, the emergence of live biotherapeutic products as novel treatment options for recurrent CDI is discussed.
本文探讨了抑郁症、肠道菌群失调和艰难梭菌感染之间错综复杂的关系,统称为“三 Ds”。抑郁症是一种普遍存在且患病率不断增加的精神障碍疾病。它以其社会负担和复杂的病理生理学为特征,包括遗传、环境和微生物群相关因素。随之而来的抗抑郁药的大量使用引发了人们对其对肠道微生物群影响的担忧。各种类别的抗抑郁药和抗精神病药都具有抗菌活性,可能导致肠道微生物群的变化,并促使菌群失调的发生。菌群失调反过来又会使个体易患艰难梭菌等机会性感染,而艰难梭菌因其高复发率和对患者生活质量的严重影响而成为一个重要的医疗保健关注点。此外,还探讨了抗抑郁药的使用与艰难梭菌感染(CDI)风险增加之间的联系,最后还讨论了新型活菌治疗产品作为复发性 CDI 的治疗选择的出现。